glp-1 cardiovascular outcomes trial results august 2025 SGLTi and in HF Emerging Frontiers in GLP-1 Therapeutics:

Manufacturers are actively developing new flavors, enhancing packaging designs, and formulating health-focused blends to attract a wider consumer base

Monitor for hypoglycemia if used with glucose-lowering medications and avoid use in those with a history of pancreatitis

For women living with obesity or weight-related health conditions, this approval represents an important expansion of treatment choice and reflects the continued evolution of obesity care

Pen cartridges can become contaminated with microscopic blood after a single use

People who struggled with weight management for years are now seeing results

The prior authorization process would delay your treatment by weeks